Investment Rating - The investment rating for the company is "Buy-A" with a 6-month target price of 136.15 CNY per share [6][9]. Core Views - The company reported a revenue of 6.67 billion CNY and a net profit attributable to shareholders of 1.13 billion CNY for 2025, representing year-on-year growth of 14.91% and 19.35% respectively [1][2]. - The company is expected to achieve a revenue growth of 19%-22% in 2026 due to continuous order growth and improving operational conditions [2][3]. - The total order backlog reached 1.385 billion USD, a year-on-year increase of 31.65%, with significant growth in orders for chemical and biological macromolecule CDMO services [3]. - The company is actively expanding its production capacity, with plans to increase the total capacity for peptide solid-phase synthesis from 45,000L to 69,000L by the end of 2026 [3]. - The company has a rich pipeline of mid-to-late stage projects, with expectations for multiple commercialized projects in both small molecule CDMO and emerging business sectors in 2026 [4]. Financial Summary - The projected net profits for the company from 2026 to 2028 are 1.40 billion CNY, 1.74 billion CNY, and 2.21 billion CNY, reflecting year-on-year growth rates of 23.8%, 24.3%, and 27.0% respectively [5]. - The company’s earnings per share (EPS) for 2026 is estimated to be 3.89 CNY, with a price-to-earnings (PE) ratio of 35 times, leading to a target price of 136.15 CNY per share [9]. - The company’s revenue is expected to grow from 5.8 billion CNY in 2024 to 12.46 billion CNY in 2028, with a compound annual growth rate (CAGR) of 23.0% [10][11].

Investment Rating - The investment rating for the company is maintained at "Buy-A" with a target price of 110.52 CNY for the next six months [4]. Core Insights - The company reported a revenue of 3.47 billion CNY for 2025, reflecting a year-over-year increase of 1.8%, and a net profit attributable to shareholders of 140 million CNY, which is a 19.4% increase year-over-year [1][2]. - In Q4, the company achieved a revenue of 1.14 billion CNY, up 1.5% year-over-year, but the net profit decreased by 60.2% year-over-year to 60 million CNY [1][2]. - The company is focusing on expanding its overseas market presence, with new product launches contributing positively to sales during key promotional periods [1]. - The domestic projection industry is facing challenges, with a reported 29% decline in online sales for the industry, while the company's online sales decreased by 23% [1]. Financial Performance Summary - Q4 net profit margin was 5.6%, down 8.7 percentage points year-over-year, attributed to lower gross margins from the automotive business and increased R&D expenses [2]. - The company’s operating cash flow for Q4 increased by 230 million CNY year-over-year, primarily due to reduced cash payments for goods and services [2]. - The projected earnings per share (EPS) for 2026, 2027, and 2028 are 4.81 CNY, 5.52 CNY, and 6.38 CNY respectively, indicating expected growth in profitability [2][3].

Investment Rating - The investment rating for the company is "Buy-A" with a 6-month target price of 31.2 CNY, while the current stock price is 25.00 CNY [5]. Core Insights - The company achieved a record high in operating performance for 2025, with total revenue of 61.687 billion CNY, a year-on-year increase of 23.31%, and a net profit attributable to shareholders of 3.643 billion CNY, up 24.26% year-on-year [1]. - The company has completed its annual production targets for copper, zinc, and lead, with copper production at 167,500 tons, slightly below the target of 168,200 tons, and lead production at 63,000 tons, achieving 96% of the target [2]. - The company has received approval for the third phase of the Yulong Copper Mine, which is expected to increase ore processing capacity significantly, and has acquired the exploration rights for the Chating Copper polymetallic mine [9][10]. Financial Performance - In 2025, the company reported a net profit of 3.643 billion CNY, with a net profit margin of 5.9% [12]. - The projected revenues for 2026 to 2028 are 67.570 billion CNY, 70.757 billion CNY, and 71.681 billion CNY, respectively, with net profits expected to be 4.955 billion CNY, 5.548 billion CNY, and 5.591 billion CNY [11][12]. - The company’s earnings per share (EPS) for 2026 is projected to be 2.08 CNY, with a price-to-earnings (PE) ratio of 12.3 [11]. Production and Pricing - The company’s copper smelting production increased by 26.69% year-on-year to 334,200 tons in 2025, while lead and zinc smelting production saw significant increases of 330.45% and 32.61%, respectively [3]. - The average copper price in 2025 was 83,012 CNY per ton, reflecting an 8.8% year-on-year increase, while lead and zinc prices experienced slight declines [3]. Strategic Developments - The company has successfully obtained mining rights for several new projects, including the Sichuan Youre Lead-Zinc Mine and the Tawan Chahanxi Iron polymetallic mine, which will enhance its resource base [10]. - The approval of the Yulong Copper Mine's third phase is expected to extend the mine's operational life and support future production increases [9].

Investment Rating - The investment rating for Hisense Home Appliances is "Buy-A" with a target price of 26.38 CNY for the next six months [4]. Core Views - Hisense Home Appliances reported a revenue of 87.93 billion CNY for 2025, a year-on-year decrease of 5.2%, and a net profit attributable to shareholders of 3.19 billion CNY, down 4.8% year-on-year. The Q4 performance showed a significant decline, with revenue of 16.4 billion CNY, down 26.0% year-on-year, and a net profit of 370 million CNY, down 32.5% year-on-year [1][2]. - The company is focusing on enhancing shareholder returns, proposing a cash dividend of 12.65 CNY per 10 shares, totaling approximately 1.75 billion CNY, which represents 54.9% of the net profit for 2025, an increase of 4.1 percentage points year-on-year [3]. Summary by Sections Financial Performance - Q4 gross margin improved to 22.3%, up 2.6 percentage points year-on-year, attributed to better capacity utilization in overseas factories and improved product mix [3]. - Q4 net profit margin was 2.3%, down 0.2 percentage points year-on-year, mainly due to increased expense ratios across sales, R&D, finance, and management [3][9]. - The company expects to improve profitability as operational efficiency in overseas factories increases and product structure continues to optimize [3]. Market Dynamics - Domestic sales were pressured in Q4 due to a sluggish real estate market, impacting central air conditioning revenue, which saw a decline of 2.9% year-on-year for domestic sales [2]. - The home air conditioning segment faced challenges with domestic sales down 21.7% and exports down 51.2% year-on-year [2]. - In contrast, the overseas markets showed promising growth, with revenue from white goods in South America, Europe, and the Asia-Pacific regions increasing by 28%, 22%, and 15% respectively [2]. Future Outlook - The company is accelerating its digital transformation and enhancing smart manufacturing capabilities, which are expected to lead to sustained improvements in production efficiency [4]. - EPS projections for 2026, 2027, and 2028 are 2.64 CNY, 2.89 CNY, and 3.12 CNY respectively, indicating a positive growth trajectory [4][10].

Investment Rating - The report assigns a "Buy-A" rating for the company with a target price of 48.64 CNY per share, while the current share price is 32.70 CNY as of March 31, 2026 [4]. Core Insights - The company is recognized as a hidden champion in the environmental additives sector, focusing on high polymer material additives for over 20 years, establishing a leading market position in the sub-segments of Saik and titanium esters with significant production capacities [1][11]. - The PVC industry is experiencing a recovery, which is expected to benefit the additives sector, as the demand for high-performance additives is anticipated to increase alongside the recovery of downstream product manufacturers [2][39]. - The supply structure for Saik is highly concentrated, with the company holding a 60% global market share and an 80% domestic market share, indicating strong demand growth in high-end applications such as electric vehicles and robotics [3][6]. Summary by Sections 1. Company Overview - The company specializes in the research, production, and sales of environmental additives, with a product system centered around Saik, titanium esters, DBM, SBM, and acetylacetone salts [1][11]. - As of the end of 2025, the production capacities for Saik and titanium esters are 34,500 tons and 8,000 tons respectively, with Saik's global market share at 60% and domestic market share at 80% [1][11]. 2. PVC Industry Recovery - The PVC market is gradually recovering, with prices increasing by 28.77% to 5,483 CNY per ton as of March 30, 2026, driven by various policy changes and market dynamics [2][39]. - The recovery in PVC is expected to enhance the demand for additives, as they play a crucial role in improving product performance and processing efficiency [2][39]. 3. Saik Supply and Demand - Saik, known for its excellent chemical and thermal stability, is primarily used as a stabilizer in various applications, with significant growth expected in high-end sectors [3][6]. - The company is expanding its applications into new fields such as polyurethane and flame retardants, which are expected to drive further demand [3][6]. 4. Financial Performance and Projections - The company anticipates revenue growth rates of -4.0%, +20.6%, and +61.6% for the years 2025 to 2027, with net profit growth rates of -15.2%, +53.5%, and +63.7% respectively [7]. - The company maintains a strong profitability profile, with gross margins for core products consistently above 30% [25][27]. 5. Market Position and Competitive Landscape - The company has established long-term partnerships with leading international groups in the insulated paint and wire industries, enhancing its competitive edge [7]. - The domestic market for titanium esters is primarily dominated by the company, which holds over 40% of the market share, indicating a strong competitive position [46].

Investment Rating - The investment rating for Hainan Mining is "Accumulate-A" with a 6-month target price of 14 CNY, compared to the current stock price of 12.04 CNY as of March 30, 2026 [4]. Core Insights - The company reported a revenue of 4.416 billion CNY for 2025, an increase of 8.62% year-on-year, but a net profit decline of 38.99% to 431 million CNY [1]. - The oil and gas production saw a significant increase, with equity production rising by 60.5% to 12.99 million barrels of oil equivalent, primarily due to the consolidation of Tethys and new wells coming online [2]. - The lithium resource business achieved a breakthrough with the launch of an integrated supply chain, producing 0.26 thousand tons of battery-grade lithium hydroxide in 2025 [3]. Summary by Sections Financial Performance - In Q4 2025, the company achieved a revenue of 1.056 billion CNY, up 18.18% year-on-year and 11.75% quarter-on-quarter, while net profit was 119 million CNY, down 25.84% year-on-year but up 271.9% quarter-on-quarter [1]. - The projected revenues for 2026 to 2028 are 6.909 billion CNY, 7.281 billion CNY, and 8.262 billion CNY, with net profits expected to be 1.117 billion CNY, 1.197 billion CNY, and 1.452 billion CNY respectively [9]. Mining Operations - The iron ore business maintained stable production, with a target of 2 million tons for 2026, supported by the completion of the magnetization roasting project [2]. - The average price for iron ore in 2025 was 102.4 USD/ton, a decrease of 6.5% year-on-year [2]. Oil and Gas Sector - The average price for Brent crude oil in 2025 was 68.2 USD/barrel, down 14.6% year-on-year [2]. - The company plans to achieve an oil and gas equity production target of 12.66 million barrels of oil equivalent in 2026 [2]. Lithium Resource Development - The company completed infrastructure for the Buguni lithium mine in January 2025, with the first batch of 30,000 tons of lithium concentrate expected to arrive in early 2026 [3]. - The lithium hydroxide project is projected to produce 20,000 tons of battery-grade lithium hydroxide, with sales expected to ramp up in 2026 [3]. Strategic Acquisitions - In 2025, the company invested 300 million CNY to acquire a 15.79% stake in Luoyang Fengrui Fluorine Industry, marking its entry into the fluorite mining sector [8]. - A further acquisition plan is set to increase the stake to 85.69% in 2026 [8].

Investment Rating - The report assigns a "Buy-A" investment rating to the company with a 12-month target price of HKD 4.86 [6]. Core Views - The company achieved a revenue of CNY 89.442 billion in 2025, representing a year-on-year increase of 2.84%, while the net profit attributable to shareholders was CNY 1.765 billion, down 19.30% year-on-year [1]. - The revenue from aviation equipment systems grew steadily, but the gross margins for both complete aircraft and supporting products faced pressure [1]. - The company is strategically investing in the development of a fully tilting flight control system, collaborating with a subsidiary to enhance its technological capabilities [3]. Financial Summary - The company's main revenue for 2025 was CNY 88.799 billion, with a projected increase to CNY 93.5 billion in 2026 and CNY 98.5 billion in 2027 [4]. - The net profit attributable to shareholders is expected to rise from CNY 1.765 billion in 2025 to CNY 1.937 billion in 2026 and CNY 2.132 billion in 2027, reflecting growth rates of 9.8% and 10.1% respectively [4]. - The average PE ratio for comparable companies is projected to be 48 and 38 times for 2026 and 2027, respectively, while the company is given a PE of 20 times for 2026 [4][11]. Company Performance - The subsidiary Hongdu Aviation reported a revenue of CNY 7.449 billion in 2025, a significant increase of 41.83% year-on-year, marking a historical high [2]. - The company’s gross margin for aviation equipment systems was 27.66%, down 3.63 percentage points year-on-year, while the gross margin for aviation engineering services improved to 12.82% [1].

Investment Rating - The report assigns a "Buy-A" investment rating to the company with a target price of 46.8 yuan for the next 12 months [4][6]. Core Insights - The company is positioned as a leading player in high-end ceramics, benefiting from significant price disparities in yttrium oxide due to geopolitical factors, which have led to a surge in overseas prices [1][2]. - The demand for MLCC (Multi-Layer Ceramic Capacitors) is expected to grow steadily, driven by the development of consumer electronics and automotive electronics, with the company poised to capture market share through domestic substitution [2][3]. - The solid-state battery segment is anticipated to show long-term value, with the company’s precision ceramics and digital printing providing stable cash flow [3]. Summary by Sections 1. High-End Functional Ceramics - The company has been deeply engaged in high-end ceramics for 20 years, establishing a platform that opens up growth opportunities across various sectors [13]. 2. Dental Restoration - The tightening of China's export policies has highlighted the price advantages of yttrium oxide, which is essential for zirconia dental materials, leading to increased demand and market share for the company [19][21]. - The global dental restoration materials market is projected to grow from $22.89 billion in 2024 to $38.22 billion by 2032, with a compound annual growth rate (CAGR) of 6.62% [21][24]. 3. MLCC Market - The demand for MLCC is expected to rise, with the global market projected to reach 132.62 billion yuan by 2029, growing at an annual rate of 4.26% [2][3]. - The company’s market share in high-end MLCC ceramic powders is expected to increase significantly due to domestic substitution trends [2][3]. 4. Policy-Driven Upgrades - Upgrades in automotive emission standards are expected to accelerate domestic substitution, providing further growth opportunities for the company [4]. 5. Diversified Business Collaboration - The company’s precision ceramics segment is projected to generate revenue of 351 million yuan in 2024, reflecting a year-on-year growth of 41.53%, while other materials will continue to provide reliable cash flow [3]. 6. Revenue and Profit Growth - The company’s net profit is expected to grow from 698 million yuan in 2025 to 1.408 billion yuan in 2027, with a significant increase in profit margins [4][9].

Investment Rating - The investment rating for the company is maintained at "Buy-A" with a 12-month target price of 129.46 CNY [4]. Core Insights - The company reported a revenue of 810 million CNY for 2025, representing a year-on-year growth of 52.07%. However, it incurred a net loss of 163 million CNY [2][4]. - The company has entered into a global development and commercialization partnership with AbbVie for ZG006, which is expected to advance overseas clinical progress. AbbVie has obtained exclusive rights for ZG006 outside Greater China, while the company retains rights within Greater China [1][2]. - The company received an upfront payment of 100 million USD in January 2026, with potential milestone payments of up to 67 million USD based on clinical progress, and up to 1.075 billion USD if AbbVie exercises its licensing option [1][2]. Financial Projections - Revenue projections for the company are estimated at 2.05 billion CNY in 2026, 2.09 billion CNY in 2027, and 2.98 billion CNY in 2028. Corresponding net profits are projected to be 665 million CNY, 443 million CNY, and 772 million CNY respectively [2][11]. - The earnings per share (EPS) are expected to be 2.51 CNY in 2026, 1.67 CNY in 2027, and 2.92 CNY in 2028 [2][11]. - The company’s total market capitalization is approximately 25.55 billion CNY [4]. Product Pipeline - The company has a robust pipeline with products such as ZG005 and ZG006 progressing rapidly. Currently marketed products include Donafenib and Jikaxitinib, among others [2][4].

Investment Rating - The investment rating for the company is maintained at "Buy-A" with a target price of 68.81 CNY per share over the next six months [5]. Core Insights - The company reported a revenue of 31.629 billion CNY for 2025, representing a year-on-year growth of 13.02%. The net profit attributable to shareholders was 7.711 billion CNY, up 21.69% year-on-year [1]. - The innovative drug cluster has entered the sales realization phase, with sales revenue from innovative drugs reaching 16.342 billion CNY, a growth of 26.09% year-on-year, accounting for 58.34% of total drug sales [1]. - The company has approximately 26 innovative drugs approved for market, with 9 new drugs expected to drive growth in 2026 [1]. - The company generated 3.392 billion CNY from licensing agreements, which has become a significant part of its revenue stream [2]. Financial Projections - Revenue projections for 2026 to 2028 are 35.956 billion CNY, 41.112 billion CNY, and 47.616 billion CNY respectively, with net profits of 9.134 billion CNY, 10.437 billion CNY, and 12.250 billion CNY [3][8]. - The expected earnings per share (EPS) for 2026, 2027, and 2028 are 1.38 CNY, 1.57 CNY, and 1.85 CNY respectively, with corresponding price-to-earnings (PE) ratios of 40.1, 35.1, and 29.9 [3][8].